Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Placental protein 13, galectin 14 and pentraxin 3 for prediction of preeclampsia in Egyptian patients

Fahmy T Ali, Ahmed M Ibrahim, Nahla S Hassan, Reham M Soliman.




Abstract

Background: Pre-eclampsia (PE) is considered one of the most dangerous pregnancy complications, and the leading cause of maternal and perinatal mortality and morbidity.

Objective: The aim of the current study was to evaluate two galectins (GAL) and some biochemical parameters in the diagnosis of PE.

Materials and Methods: The study included a total of 96 women, including 66 pregnant women with PE, and 30 normotensive pregnant females. The biomarkers studied, at the 3 trimesters, included GAL13 and 14, pentraxin 3 (PTX3), C-reactive protein (CRP), liver function tests, and lipid profile.

Results: Results indicated that a significant difference in GAL13 and 14 and PTX3 in preeclamptic women compared to normotensive pregnant ones. The level of CRP showed non-significant change in all patient’s groups. Liver function tests, total cholesterol, low-density lipoprotein cholesterol, and triacylglycerols revealed a high significant increase in all patient’s groups. Levels of high-density lipoprotein cholesterol were highly significant decreased in 2nd and 3rd-trimester patients.

Conclusion: The specificity and sensitivity of GAL14 provided the highest diagnostic information of these biomarkers and are in close to GAL13 and PTX3; while, CRP yielded a significantly worse accuracy for diagnosing PE.

Key words: Preeclampsia; Galectins 13; Galectins 14; Pentraxin 3






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.